Positive new data on daratumumab in relapsed or refractory multiple myeloma

31 March 2016

Danish biotech company Genmab (OMX: GEN) has released positive top-line data on its daratumumab in the treatment of multiple myeloma, resulting in the firm’s shares rising 3.7% to 890.50 Danish kroner in early trading.

The drug is being co-developed with Janssen-Cilag, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), to which Genmab granted an exclusive worldwide license for daratumumab in August 2012.

Genmab announced today that the Phase III Castor study (MMY3004) of daratumumab in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma met the primary endpoint of improving progression free survival (PFS) in an interim analysis (p =< 0.0001). The planned interim analysis was conducted by an Independent Data Monitoring Committee (IDMC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK